OGN Stock Recent News
OGN LATEST HEADLINES
JERSEY CITY, N.J.--(BUSINESS WIRE)--Organon announces the appointment of Ramona A. Sequeira to the company's Board of Directors, effective July 1, 2025.
JERSEY CITY, N.J.--(BUSINESS WIRE)--Organon will host Q1 2025 earnings results webcast and conference call on May 1, 2025.
Organon (OGN) closed the most recent trading day at $11.30, moving +1.07% from the previous trading session.
Organon (OGN) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.
Organon (OGN) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.
Why investors should use the Zacks Earnings ESP tool to help find stocks that are poised to top quarterly earnings estimates.
Organon (OGN) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
Zacks.com users have recently been watching Organon (OGN) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.
JERSEY CITY, N.J.--(BUSINESS WIRE)--Organon announced it has acquired regulatory and commercial rights in the U.S. for TOFIDENCE™, a biosimilar to ACTEMRA®, for intravenous infusion.
SHANGHAI, China & JERSEY CITY, N.J.--(BUSINESS WIRE)--Henlius and Organon announced the European Medicines Agency validates filing for Perjeta® (pertuzumab) Biosimilar Candidate HLX11.